The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) is a huge mover today! About 152,678 shares traded hands. SAGE Therapeutics Inc (NASDAQ:SAGE) has risen 20.53% since March 7, 2016 and is uptrending. It has outperformed by 12.94% the S&P500.
The move comes after 6 months positive chart setup for the $1.66B company. It was reported on Oct, 10 by Barchart.com. We have $60.92 PT which if reached, will make NASDAQ:SAGE worth $564.40 million more.
Analysts await SAGE Therapeutics Inc (NASDAQ:SAGE) to report earnings on November, 3. They expect $-1.11 EPS, down 32.14% or $0.27 from last year’s $-0.84 per share. After $-1.08 actual EPS reported by SAGE Therapeutics Inc for the previous quarter, Wall Street now forecasts 2.78% negative EPS growth.
SAGE Therapeutics Inc (NASDAQ:SAGE) Ratings Coverage
Out of 9 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 7 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 78% are positive. SAGE Therapeutics has been the topic of 10 analyst reports since September 3, 2015 according to StockzIntelligence Inc. The company was maintained on Thursday, September 3 by Leerink Swann. The firm has “Sell” rating given on Tuesday, May 24 by Chardan Capital Markets. On Wednesday, March 30 the stock rating was initiated by Goldman Sachs with “Neutral”. JP Morgan maintained the shares of SAGE in a report on Thursday, September 3 with “Buy” rating. The firm has “Outperform” rating given on Tuesday, September 13 by Raymond James. The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) earned “Outperform” rating by BMO Capital Markets on Wednesday, June 29. The rating was initiated by Lake Street with “Buy” on Friday, March 11. The firm has “Buy” rating by H.C. Wainwright given on Thursday, June 23.
According to Zacks Investment Research, “SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1.51 in Q2 2016. Its down 0.73, from 2.24 in 2016Q1. The ratio dropped, as 28 funds sold all SAGE Therapeutics Inc shares owned while 27 reduced positions. 23 funds bought stakes while 60 increased positions. They now own 29.30 million shares or 2.83% more from 28.49 million shares in 2016Q1.
Northern owns 283,797 shares or 0% of their US portfolio. Oak Ridge Invs Ltd Liability Corp has invested 0.49% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). Teachers Advisors has 42,877 shares for 0% of their US portfolio. Huntington Comml Bank holds 0% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE) for 13 shares. Metropolitan Life Ny has 19,722 shares for 0% of their US portfolio. The New York-based Jpmorgan Chase And has invested 0.01% in SAGE Therapeutics Inc (NASDAQ:SAGE). Nationwide Fund Advisors has invested 0% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). The New Jersey-based Sabby Mgmt Ltd Liability Com has invested 0.11% in SAGE Therapeutics Inc (NASDAQ:SAGE). Visium Asset Mngmt Limited Partnership owns 7,395 shares or 0.02% of their US portfolio. Tekla Capital Llc accumulated 0.18% or 146,800 shares. The New York-based Rockefeller Incorporated has invested 0% in SAGE Therapeutics Inc (NASDAQ:SAGE). Ubs Oconnor Limited Company accumulated 18,960 shares or 0% of the stock. New York State Common Retirement Fund reported 16,500 shares or 0% of all its holdings. Dekabank Deutsche Girozentrale has 16,950 shares for 0.01% of their US portfolio. Deutsche Financial Bank Ag has invested 0.01% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE).
Insider Transactions: Since April 19, 2016, the stock had 0 insider buys, and 6 selling transactions for $55.15 million net activity. 2,500 shares with value of $102,325 were sold by IGUCHI KIMI on Wednesday, September 7. Robichaud Albert had sold 22,000 shares worth $880,000. The insider Kanes Stephen sold 21,000 shares worth $798,000. On Monday, May 16 the insider Third Rock Ventures II – L.P. sold $26.56M. STARR KEVIN P also sold $26.56 million worth of SAGE Therapeutics Inc (NASDAQ:SAGE) shares.
More notable recent SAGE Therapeutics Inc (NASDAQ:SAGE) news were published by: Fool.com which released: “Here’s Why SAGE Therapeutics Inc. Is Surging Today” on July 12, 2016, also Marketwatch.com with their article: “Sage Therapeutics stock rises 12% after FDA designates drug a ‘breakthrough …” published on September 06, 2016, Prnewswire.com published: “Biotech Stocks Technical Reports — Tesaro, CTI BioPharma, Sage Therapeutics …” on October 07, 2016. More interesting news about SAGE Therapeutics Inc (NASDAQ:SAGE) were released by: Valuewalk.com and their article: “SAGE Therapeutics Inc (SAGE) – Debunking Asclepia Capital” published on April 01, 2016 as well as Valuewalk.com‘s news article titled: “SAGE Therapeutics Inc (SAGE) Overhyped Lead Drug Headed for Failure â€“ Kerrisdale” with publication date: March 23, 2016.
SAGE Company Profile
SAGE Therapeutics, Inc., incorporated on April 16, 2010, is a clinical-stage biopharmaceutical company. The Firm is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also targets the GABAA receptor system. The Firm is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.